未定位的尿路蛋白质学揭示了肥胖手术诱导的减肥后的脏保护和全身适应
Pedro R Pereira1,2,3, David F Carrageta2,3, Bárbara Guerra-Carvalho2,3,4
1Department of Nephrology, Unidade Local de Saúde de Santo António (ULS Santo António) - Porto, Largo Professor Abel Salazar, 4099-001 Porto, Portugal.
Journal of proteome research
|December 10, 2025
概括
减肥手术 (BS) 显著改变尿蛋白,揭示了免疫功能,适应和细胞组织的变化. 这些发现突出了BS诱导的减肥后系统性健康益处和脏保护的潜在机制.
科学领域:
- 蛋白质组学是指蛋白质组学.
- 代谢手术 代谢手术
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 减肥手术 (BS) 诱导大量的体重减轻,影响多个生物系统.
- 了解BS后的全身和适应对于管理与肥胖有关的并发症至关重要.
研究的目的:
- 确定反映肥胖患者脏和全身适应的尿蛋白,在减肥手术前后.
- 探索BS诱导的减肥对尿蛋白质组的影响.
主要方法:
- 在BS (n=16) 之前和两年后从肥胖个体收集尿液样本.
- 使用非定位的高分辨率液态染色体质谱法 (LC-MS) 进行无标签量化.
- 分析了蛋白质组的变化,确定了显著改变的蛋白质丰度 (p < 0.05).
主要成果:
- 鉴定了2347种尿蛋白;1016种在BS后显著的丰度变化.
- 观察到54种蛋白质的实质性变化 (≥1.5倍变化),包括与免疫功能,细胞骨/细胞粘附和适应相关的蛋白质.
- 检测到炎症标志物减少 (例如,α-1-酸糖蛋白) 和免疫调节/氧化应激保护蛋白增加 (例如,二 dipeptidase 1).
结论:
- 在BS后的尿蛋白质组变化表明炎症,氧化应激,功能和细胞组织的显著变化.
- 这些发现表明,BS诱导的体重减轻的系统性修饰和保护作用涉及新的途径.
- 尿蛋白分析提供了关于减肥手术后多面性适应的见解.
关键词:
减肥干预措施 减肥干预质谱测量质谱测量质谱测量质谱测量质量测量质谱测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖肥胖外科手术 肥胖外科手术与肥胖相关的脏疾病.尿中的蛋白质组学更多相关视频
相关概念视频
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
159
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
159
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
221
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
221
01:21Drug Dosing: Obese Patients
198
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
198
01:26Nephrotic Syndrome II : Assessment and Medical Management
180
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
180
01:24Nephrotic Syndrome I : Introduction
469
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
469